Trial Profile
A proof-of-concept study of psilocybin for treatment-resistant depression in patients in a clinical setting
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Oct 2018
Price :
$35
*
At a glance
- Drugs Psilocybin (Primary)
- Indications Depression; Depressive disorders
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- 30 Oct 2018 New trial record
- 23 Oct 2018 According to a COMPASS Pathways media release, the Medical Research Council supported this trial in 2015.